UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
FUSION PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Canada | Not Applicable | |
(State of incorporation or organization) | (I.R.S. Employer Identification No.) | |
270 Longwood Road South Hamilton, Ontario, Canada | L8P 0A6 | |
(Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered | Name of each exchange on which each class is to be registered | |
Common shares, no par value per share | The NASDAQ Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement file or Regulation A offering statement number to which this form relates (if applicable):
333-238968
Securities to be registered pursuant to Section 12(g) of the Act:
None
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. | Description of Registrant’s Securities to be Registered. |
For a description of the Registrant’s common shares, no par value per share (the “Common Shares”), to be registered hereunder, reference is made to the information set forth under the heading “Description of Share Capital—Common Shares” in the Registrant’s prospectus that constitutes a part of the Registrant’s Registration Statement on FormS-1, as amended (FileNo. 333-238968) (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), which information is hereby incorporated by reference. The description of the Common Shares included in any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act shall be deemed to be incorporated by reference herein.
Item 2. | Exhibits. |
In accordance with the “Instructions as to Exhibits” with respect to Form8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
FUSION PHARMACEUTICALS, INC. | ||||||
Date: June 23, 2020 | By: | /s/ John Valliant | ||||
John Valliant | ||||||
Chief Executive Officer |